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Abstract 
Despite decreasing incidence in cervical cancer in the U.S., there continues to be an 
increase in public health concern for cervical cancer worldwide. Recent studies report that 
individuals are disproportionately affected based on region, sex, and race. Additionally, the 
human papillomavirus (HPV) attributable cancers may be reduced between 70% and 90% 
through the universal use of HPV-vaccines. In order to expand current knowledge and implement 
intervention programs in Nevada, it is critical to examine the associations among the Gardasil 
vaccine, cervical cancer screening, and adverse events following immunization as well as to 
understand the different socio-demographic subgroups affected. To our knowledge, this study 
provided a novel analysis of the Gardasil vaccine usage trends within Nevada and will use an 
adjacent state (California) and the U.S. as comparators. This study used 2008-2018 data from 
TeenVaxView, Behavioral Risk Factor Surveillance System (BRFSS), and Vaccine Adverse 
Event Reporting System (VAERS) data reporting adverse events following an HPV vaccination. 
We found that California (68.4%) had the highest Gardasil vaccine usage compared to Nevada 
(55.9%) and the U.S. (56.4%). Chi-square trend analysis in this study showed no significant 
change in cervical cancer screening in Nevada (p=0.829); however, chi-square test for trend in 
California did show a significant change through time (p<0.001). Kolmogorov-Smirnov (KS) 
test with a Bonferroni adjustment examining the differences among curves representing outcome 
temporal rates for Nevada compared to California showed a significant difference (p=0.031). No 
association was seen between Gardasil vaccine estimates and cervical cancer screening rates. 
There was also no association between Gardasil estimates and adverse events through time in 
Nevada or the U.S.  
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 The human papillomavirus (HPV) is one of the most common sexually transmitted 
infections (STI) worldwide and results in a considerable amount of morbidity and mortality as 
discussed below. HPV belongs to the Papillomavirus genus and Papillomaviridae family and has 
more than 100 different HPV types that are the causative agents of the human HPV-related 
infections, cancers, precancerous or dysplastic lesions, and genital warts (Bernard et al., 2010; 
Kumakech, 2015; Planned Parenthood, 2015).  
 Most cases of HPV will resolve within 2 years of infection and many cases of infection 
will be asymptomatic and have no clinical manifestations (CDC, 2019a; CDC, 2019b; NIH 
2020). However, according to the CDC, some possible clinical manifestations of HPV infection 
include anogenital warts, recurrent respiratory papillomatosis, cervical cancer precursors 
(cervical intraepithelial neoplasia), and cancers (CDC, 2019b).  
There are four types of warts that can occur as a result of the more than 150 different 
HPV types including common skin warts, flat warts, plantar warts, and genital warts (Harvard 
Medical School, 2019; Mayo Clinic, 2019b). The most common clinical presentation of HPV is 
genital warts, which are typically painless growths that have a rough, cauliflower-like 
appearance that may cause itching or tenderness of the area (i.e., tip of penis, opening of urethra, 
skin around the anus, vagina, labia, vulva, or cervix) (Harvard Medical School, 2019; Mayo 
Clinic, 2019b). 
Furthermore, certain HPV types can also lead to precancerous or dysplastic lesions and 
invasive cervical cancer if a persistent infection does not resolve on its own through the help of 
the body’s immune system. The development of cervical dysplasia indicates that there are 
abnormal cells on the cervix that can range from mild to severe depending on histological 
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presentation (Mayo Clinic, 2018). Precancerous lesions attributed to HPV have abnormal cell 
appearance that occurs as a result of changes in the skin and mucous membrane where HPV 
infection occurred (Anal Cancer Foundation, n.d.). Early stages of cervical cancer are not usually 
detectable or show any symptoms; however, later stages of cervical cancer can cause vaginal 
bleeding, unusual vaginal discharge, pelvic pain, and pain during sexual intercourse (NIH, 2019 
& 2020).  
It is difficult to assess the case fatality rates of HPV infections. However, based on the 
types of cancers associated with HPV there has been extensive research done on deaths 
associated with cervical cancer. Approximately 311,000 women died of cervical cancer in 2018 
because of an HPV infection (WHO, 2019). Of the almost 200,000 cervical precancer cases that 
are found in the U.S. each year, 11,000 cases were cervical cancer within approximately 4,000 of 





Background and Significance 
Through the implementation of the nonvalent HPV vaccine, the potential to reduce the 
preventable fraction of HPV globally would be roughly 50%, hence making cervical cancer one 
of the most preventable cancers in the U.S. (McDougall et al., 2007; de Martel et al., 2017; 
Moore et al., 2018; de Sanjose et al., 2019). There are more than 12,900 newly diagnosed cases 
of cervical cancer and more than 4,100 annual deaths per year (McDougall et al., 2007; Yoo et 
al., 2017; Moore et al., 2018). When diagnosed early, the overall survival rate for cervical cancer 
has increased to an estimated 5-year rate of 90.8% (Churilla et al., 2016; Moore et al., 2018). 
There are several studies (outlined below) that show that treatment and survival from these 
cancers is dependent on disparities that exist within the U.S.  
Although the incidence of invasive cervical cancer has declined overall in the U.S., 
African American and Hispanic women continue to have the highest incidence of cervical cancer 
(16.3/100,000 and 24.2/100,000, respectively) compared to their non-Hispanic white 
counterparts (10.8/100,000) (McDougall et al., 2007). Disparities in morbidity and mortality can 
also be found based on health insurance coverage (Churilla et al., 2016). Of the 11,714 cases that 
Churilla and colleagues (2016) identified, the International Federation of Gynecology and 
Obstetrics (FIGO) scoring methods that had late-stage presentation was found most frequently in 
Medicaid (40%; p<0.001) and uninsured patients (42%; p<0.001) compared to privately insured 
patients (28%; p<0.001). According to Churilla and colleagues (2016), mortality rates were 
higher in uninsured and Medicaid patients (OR=1.17; 95% CI [1.01-1.34] and OR=1.16; 95% CI 
[1.05-1.28]), respectively). 
There continue to be significant health disparities associated with cervical cancer 
screening by race, income, education, health insurance coverage and geographic region. When 
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assessing cervical screening rates in the U.S. by race, Native Hawaiian/other Pacific Islanders 
had the lowest number of screenings (0.1%), followed by Asians (0.7%) with the highest 
screening rates among White non-Hispanics followed by Hispanic/Latino subgroups (Miles-
Richardson, 2017). In a review conducted by Mann and colleagues (2016), they found that in 
Hispanic/Latin women specifically, there were many barriers to cervical cancer screenings such 
as socio-cultural-, system-level and lack of education. In a 2017 study, researchers found that 
low income level (<%24,999) had the highest screening rates compared to those all other income 
levels (Miles-Richardson et al., 2017). In a recent study, researchers found that women who were 
foreign-born and who had spent less time living the U.S. influenced whether they had a Pap test 
compared with U.S.-born women (Endeshaw et al., 2018). There is approximately 90% of 
women in the U.S. reporting having screening within 5 years. Investigators argue the need to 
target unscreened women to get screened versus those who are under- or over- screened, 
reporting that targeting these women will have a better value when the amount that can be spent 
improving adherence was estimated under scenarios of current practice (Castle et al., 2018).  
Additionally, living in specific regions of the U.S. can positively impact screening and 
vaccine rates based on race subgroups (Domgue et al., 2019; Hirth 2019). Research has shown 
that there have been statistically significant increases in cervical cancer screening where 
interventions were clinic-based, used lay health advisors (i.e., cancer survivors, members of 
churches, community members), used behavioral theory (i.e., social influence theory, popular 
education and adult education theory) (Mann et al., 2015). 
The best way to prevent an HPV infection would be through sex abstinence (i.e. vaginal, 
anal, oral sex, or any other genital contact), which is extremely difficult to do since most people 
will have some form of sexual contact in their lifetime (Planned Parenthood, n.d.). Therefore, the 
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next best thing to do for population-level control measures of HPV infections would be to get the 
HPV vaccine early (in children 11-12 years), preferably prior to first intimate contact (CDC, 
2019c; Planned Parenthood, n.d.). Alternatively, the use of condoms and/or dental dams would 
provide protection any time individuals engage in sexual contact of the vagina, anus or mouth in 
order to decrease their risk of getting HPV (Planned Parenthood, n.d.). It is also recommended 
that individuals wait at least 2 weeks after genital warts have gone away prior to engaging in sex 
again (NY State Department of Health, 2018). 
There is no cure for HPV; however, as mentioned above, most infections go away on 
their own within 1-2 years; however, some treatments targeting the health problems caused by 
the infection exist (CDC, 2019a; CDC, 2019b; NIH 2020). External genital and perianal warts 
caused by HPV may be treated by healthcare providers through medications (i.e., salicylic acid, 
imiquimod 3.75%, podofilox 0.5%, trichloroacetic acid or bichloroacetic acid 80-90%), 
cryotherapy (liquid nitrogen freezing of warts), electrocautery treatment (burning warts with an 
electrical current), excision of warts and laser surgery removal of warts (CDC, 2015b; Mayo 
Clinic, 2019a). Additionally, there are certain procedures that be conducted by a healthcare 
provider if the genital warts are not visible to the naked eye, such as the vinegar (acetic acid) 
solution tests, which turns the HPV infected areas white, a Pap tests, which can show cell 
abnormalities after a pathologist reviews the culture, and DNA tests can be conducted on the 
cells from the cervix to look for DNA of a variety of HPV types (Mayo Clinic, 2019a).  
There are currently three HPV vaccines that have been approved by the FDA. The first 
vaccine approved by the U.S. Food and Drug Administrations (FDA) in 2006 was the 
quadrivalent HPV vaccine (Gardasil) that protects against HPV types 6, 11, 16, and 18, which 
are the most common HPV types to cause genital warts (6 & 11) and cervical cancer (16 & 18) 
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(FDA, 2018). The quadrivalent HPV vaccine was originally approved for use in women between 
11-26 years; however, it was later approved for use in both males and females between the ages 
of 9-26 years (FDA, 2018). In 2009 the FDA approved the second HPV vaccine (Cervarix), and 
it was approved for use in women, between 9-26 years, only to protect them against the common 
HPV types (HPV types 16 and 18) that cause cervical cancer (FDA, 2019). The most recent 
vaccine approved by the FDA in 2014 was Gardasil 9, a nine-valent vaccine that provides 
protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 that may cause cervical, 
vulvar, vaginal, penile and anal cancers, as well as any precancerous or dysplastic lesions or 
genital warts (Merck Vaccines, 2019). The nine-valent vaccine is approved for use in males and 
females between 9-45 years. 
 The current CDC recommendations for HPV vaccination is for males and females 
between the ages of 9-26 years, but they highly recommend that two doses of the HPV vaccine 
be given to boys and girls between the ages of 11-12 (CDC, 2019c). Although there is FDA 
approval for the use of Gardasil 9 in older adults between the ages of 27-45 years, the HPV 
vaccine should ideally be administered prior to first intimate contact (vagina, anal or oral sex), 
which would be prior to first exposure to HPV infection in order to be most effective in 
preventing HPV attributable cancers (CDC, 2019c; Merck Vaccines, 2019). Hence, any HPV 
vaccines in the older populations may prove to be less beneficial of they have already been 
exposed to HPV. 
 Data for women who received all three doses of any of the three HPV vaccines (bivalent, 
quadrivalent, nine-valent) in clinical trials both demonstrated efficacy of over 90% against 
persistent HPV infections that were caused by HPV types 16 or 18 and they could all prevent 
more than 400,000 HPV-related cancers worldwide (Cutts et al., 2007; Serrano et al., 2018). 
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Additionally, the HPV vaccines are designed to be prophylactic and data on the efficacy, 
immunogenicity and safety of the vaccines in women who have already been exposed to HPV 
(genotypes 16 and 18) did not show a protective effect against cervical intraepithelial neoplasia 
(CIN) 2/3 or cervical adenocarcinoma in situ (AIS) compared to women who did not have 
evidence of past HPV infection (Cutts et al., 2007). 
The HPV vaccines are the best public health tool for the prevention and/or eradication of 
many cancers; however, vaccines do not come without limitations and it is important to establish 
the safety of the HPV vaccines. Much of the current literature suggests similar common adverse 
events occurring following immunization with an HPV vaccine. In studies assessing venous 
thromboembolic events (VTE) following the HPV vaccine, studies have found there to be no 
serious concerns associated with VTE (Lui et al., 2016; Mauro et al., 2019; Naleway et al., 
2016). Guillain-Barré Syndrome (GBS) findings were mixed reviews in terms of frequency of 
events and severity in various studies and none of the studies reported an incidence over rate 
0.01/100,000 vaccine dosages (Slade et al., 2009; Gee et al., 2017; Mauro et al., 2019). Among 
the most common adverse events were syncope, dizziness, headaches, nausea, vomiting, 
autoimmune disorders, and hypersensitivity reactions are among the most common adverse 
events reported in various studies and differed in severity (Slade et al., 2009; Arana et al., 2018; 
Mauro et al., 2018; Suragh et al., 2018). 
Furthermore, a study found headaches (n=152, 11.0%, 4.5/100,000 doses administered), 
nausea (n=125, 9.1%, 3.7/100,000 doses administered), and vomiting (n=66, 4.8%, 1.9/100,000 
doses administered) to be among the most frequently reported systematic events reported in a 
Sao Paulo, Brazil study (Mauro et al., 2019). There were similar findings reported in U.S. studies 
where headaches were reported a total of 937 times, 84% were nonserious events and 16% of 
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headaches were considered serious adverse events based on hospitalization for neurologic 
evaluation after fall-related syncope (Slade et al., 2009). Additional Vaccine Adverse Event 
Reporting System (VAERS) data indicates that headaches were among the most frequently 
reported non-serious and serious AE in both females (10.5% and 29.1%, respectively) and males 
(8.7% and 28.0%, respectively) immunized with an HPV vaccine (Arana et al., 2018). There was 
also some slight variability in report severity associated with nausea. Females reported 8.6% of 
non-serious nausea events and males reported no non-serious nausea events, whereas both 
females and males reported serious events of nausea with female reports being slightly higher 
than males (21.6% and 20.3%, respectively) (Arana et al., 2018). Given the variation in reported 
adverse events in previous studies, it is important to establish clear vaccine safety in the U.S.  
Purpose 
 The purpose of this study was to provide a first-time descriptive analysis of the use of the 
Gardasil vaccine within Nevada compared to California and the U.S. This study analyzed 2008-
2018 CDC VaxView data, BRFSS data, and VAERS, the frequency of the use of the Gardasil 
vaccine and cervical cancer screening within Nevada compared to California and the U.S. 
Additionally, the difference in Gardasil vaccine patterns based on sociodemographic subgroups 
within Nevada compared to California and the U.S were assessed. In this study we determined if 
there was a difference between Gardasil vaccination rates and reported rates of cervical cancer 
screening in Nevada, California and the U.S. Lastly, an association was investigated between 
Gardasil adverse events by sex in Nevada, California, and the U.S. 
Research Questions 
 Given the disparities in the use of HPV vaccines and cervical cancer screening by 
sociodemographic subgroups, this study will supplement current literature by explicitly 
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examining available subgroup data (McDougall et al., 2007; de Martel et al., 2017 & 2019; 
Phaswana-Maguya & Peltzer, 2017; de Sanjose et al., 2019). Additionally, there have been no 
previous studies assessing HPV vaccine use and cervical cancer screening studies comparing 
Nevada to California and the U.S. It is also critical to establish safety in the HPV vaccine and to 
our knowledge, there are no studies assessing how Nevada compares to the U.S. in adverse 
events following immunization with an HPV vaccine. Currently, only 3 U.S. states (Hawaii, 
Rhode Island, and Virginia) and the District of Columbia have mandated the HPV vaccine in 
elementary and secondary schools (Immunization Action Coalition, 2019).The U.S. is 
approximately 30% below the Healthy People (HP) 2020 goal for adolescents between 13 
through 15 years who received 2 or more doses of the HPV vaccine (HP2020, n.d.a). Hence, 
there is a need to increase vaccine uptake in adolescents across the U.S. to reach HP 2030 goals 
of 80% from our current 48.0% baseline (HP2020, n.d.b). Lower vaccination rates and higher 
cervical cancer rates have been found in Nevada compared to national averages making Nevada 
an important target for assessment (Chen et al., 2020;(U.S. Cancer Statistics Working Group, 
2020). Therefore, Nevada was also selected for this study given the state’s large number of rural 
counties with lower healthcare access, which may be attributing to the decrease in vaccine 
uptake and screening. California was chosen as a comparison state in this study given its large 
population size and similar age and race distribution compared to Nevada (U.S. Census Bureau, 
n.d.). The following questions will be investigated:  
1. How do Gardasil vaccination rates in Nevada compare to California and to the U.S.?  
2. How do cervical cancer rate in Nevada compare to California and to the U.S.? 
3. What are the sociodemographic subgroups and Gardasil vaccine patterns of those 
subgroups within Nevada, California, and the U.S.?  
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4. Are there any potential temporal associations between Gardasil vaccination rates and 
reported cervical cancer screening rates in Nevada, California, or the U.S.?  
5. Are there any potential temporal associations between Gardasil vaccination rates and 
reported adverse events following HPV vaccination in Nevada, California, and the U.S.? 
Objectives 
The following objectives will be examined in Nevada compared to California and the U.S. 
Objective 1 
 To determine the frequency use of Gardasil  
Objective 2 
 To determine cervical cancer screening rates 
Objective 3 
 To determine the difference in Gardasil vaccine patterns based on sociodemographic 
subgroups. 
Objective 4 
 To determine if there is a difference between Gardasil vaccination rates and reported 
rates of cervical cancer screening. 
Objective 5 
To determine if there is an association between Gardasil vaccination rates and reported 
adverse events following HPV vaccination. 
Hypothesis 
Hypothesis 1 
H0: There will be no difference in the use of Gardasil in Nevada compared to California 
and the U.S. 
11 
 
Ha: There will be a difference in the use of Gardasil in Nevada compared to California 
and the U.S. 
Hypothesis 2 
 H0: There will be no difference in cervical cancer screening rates in Nevada compared to 
California and the U.S. 
 Ha: There will be a difference in cervical cancer screening rates in Nevada compared to 
California and the U.S. 
Hypothesis 3 
H0: There will be no difference in Gardasil vaccine patterns based on sociodemographic 
subgroups in Nevada compared to California and the U.S. 
Ha: There will be a difference in Gardasil vaccine patterns based on sociodemographic 
subgroups in Nevada compared to California and the U.S. 
Hypothesis 4 
Ho: There will be no association between Gardasil vaccination rates and reported rates of 
cervical cancer screening in Nevada, California, and the U.S. 
Ha: There will be an association between Gardasil vaccination rates and reported rates of 
cervical cancer screening in Nevada, California, and the U.S. 
Hypothesis 5 
Ho: There will be no association between Gardasil vaccination rates and reported adverse 
events following HPV vaccination in Nevada compared to California and the U.S. 
Ha: There will be an association between Gardasil Vaccination rates and reported adverse 




 All data retrieved from the CDC TeenVaxView, the BRFSS, and the VAERS databases 
have been de-identified making this study a secondary data analysis and was deemed exempt 





The present study is a cross-sectional, population-based descriptive study that utilized 
data from the CDC TeenVaxView database, BRFSS, and VAERS database. Additionally, this 
study was largely descriptive a study. TeenVaxView data is collected through the National 
Immunization Survey-Teen (NIS-Teen), which consists of a random-digit-dialing survey of 
parents or guardians of adolescents between the ages of 13-17 years. The NIS-Teen telephone 
survey is followed-up by a questionnaire that is mailed to the adolescents’ healthcare provider to 
obtain their vaccination history (CDC, 2017). 
The data from BRFSS was retrieved for this assessment and is a cross-sectional study 
composed of adults over the age of 18 years (CDC, 2018). BRFSS is one of the largest health 
surveys in the world and on average the BRFSS completes more than 400,000 surveys annually 
(CDC, 2014b). Participants are surveyed nationally in all 50 states, the District of Columbia 
(D.C.), Puerto Rico, Guam, and the U.S. Virgin Islands (CDC, 2014). Telephone surveys are 
conducted by state health departments and they receive technical and methodological assistance 
from the CDC as needed (CDC, 2014). The landline and cell phone numbers selected for the 
survey are obtained through random sampling (CDC, 2018). This survey consists of a 
questionnaire that is composed of three components: the core component, the optional module, 
and the state added questions (CDC, 2014).  
The VAERS database is a self-report early warning system used to detect potential safety 
issues in licensed vaccines in the U.S. VAERS is managed by both the Centers for Diseases 
Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA). VAERS uses 
passive surveillance where individuals are encouraged to report any adverse events (side effects) 
as a result of any vaccine received. Healthcare professionals and vaccine manufacturers are also 
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required to report all adverse events that they may encounter. Information entered into the 
VAERS database includes information on the patient, the vaccine type, and the adverse event 
reported.  
Study Sample 
 Between 2008 -2018, there were approximately 2,328 teens who participated in the NIS-
Teen survey. 132,587 participants that self-reported adverse events related to an HPV vaccine to 
the VAERS database between 2008-2018. Additionally, there were 82,497 participants on the 
BRFSS that participated in the Pap screening, where 6,8146 of those women reported having a 
pap test within the past 3 years. 
Statistical Analysis 
Data for this study was analyzed using the IBM SPSS Statistics 26.0 software. 
Descriptive statistics were calculated to find Gardasil vaccine frequency and cervical cancer 
screening rates in Nevada, California and the U.S. and to calculate differences between Gardasil 
vaccine patterns based on sociodemographic subgroups in Nevada compared to California and 
the U.S. Gardasil vaccination rates in Nevada, California, and the U.S, were calculated by 
dividing the number of Gardasil vaccines given between 2008-2018 and cervical cancer 
screening rates in Nevada, California, and the U.S. A chi-square test for trend was used to look at 
trends through in California and Nevada only. Lastly, a Kolmogorov-Smirnov (KS) test along 
with a Bonferroni adjustment was utilized to examine any differences among the curves for 






 According to 2008-2018 TeenVax View data, 191,301 teens between the ages of 13-17 
years received an HPV vaccine and of those teens, 3,025 and 3,520 were vaccinated in Nevada 
and California, respectively. Results below indicate that vaccine coverage estimates have been 
relatively stable through time and there is no significant difference in the use of Gardasil rates in 
Nevada compared to California and the U.S.  
Frequencies for HPV vaccines administered for the US, California and Nevada can be 
found in Table 1. Overall, Nevada has been roughly in between the vaccine coverage estimates 
for California and the US with a peak in vaccine coverage estimates in 2015 that surpassed that 
of the U.S. and California (Figure 1). In Nevada There have also been an upwards trend in 
female vaccine coverage estimates through time (Figure 2). However, since the recommendation 
to vaccinate boys in 2011, there has been over 50% increase in vaccine coverage for boys in 






Figure 1. Vaccine coverage rates (%) through time for California, Nevada, and the US. 
 
 
Nevada tends to have Gardasil vaccine usage, by gender, that lies between California and 
the U.S. (Figures 2 and 3). Nevada has been slightly below California gender vaccine usage in 
every year except for in 2015 where Nevada (72.0%) surpassed California (66.7%) vaccine 
usage in females (Table 1). Overall, California had the highest Gardasil usage compared to 
Nevada and the U.S. for both genders except for 2018 where the U.S. female vaccine usage was 
























Figure 2. Female vaccine coverage rate (%) through time for California, Nevada, and the US. 
 
 
Table 1. Gender vaccine frequencies through time by sex. Numbers provided as n (%). 
 
2008 2009 2010 2011 2012 2013 
 Female Female Female Male Female Male Female Male Female Male 
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Note. Male data was not available for 2008-2009.  

























      Figure 3. Male vaccine coverage rates (%) through time for California, Nevada, and the US. 
 
 
Cervical Cancer Screening Rates 
The chi-square test for trend of Papanicolaou (pap) testing in California indicated that 
there has been a change in screening proportion rates through time (p<0.001) (Table 2). Based on 
p<0.05 significance level, California screening proportions in 2008 (84.1%) differed from 
screening proportions in 2010 (81.7%), 2012 (80.7%), 2014 (76.2%) and 2018 (80.7%) (Table 
2). Based on the chi-square test for trend, in Nevada, we found that the screening proportion 
rates do not change through time (p=0.829) (Table 2). However, in Nevada there was less 
screening in 2012 (72.8%) compared to 2008 (78.0%) and 2014 (79.5%) (Table 2). Furthermore, 
screening proportion rates in Nevada only differed in 2008 (78.0%) and 2012 (72.5%) with a 
p<0.05 significance level (Table 2). In the U.S., no chi-square test for trend was completed for 
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Yes 82.9 81.3 78.0 75.2 79.8 85293 
(80.2) 
 
No 17.1 18.7 22.0 24.8 20.2 20871 
(19.8) 
 
Note. *Chi-square test for trend p-value with a p<0.05 significance level.  
¥ Kolmogorov-Smirnov Z test proportion p-value at p<0.05 significance level. 
**Median value reported with no confidence intervals for the U.S. 
Subscript letter denotes a subset of Year categories whose column proportions by state do not differ significantly from each other at 
the p<0.05 level  
 
 
Trend analysis for the U.S., California and Nevada showed that they all had over 70% 
screening rates since 2008 (Figure 4). Between 2008-2012, Nevada had approximately 6% lower 
screening rates compared to California and the U.S. (Table 2). The two-sample K-S test showed 
there was a difference between cervical cancer screening rates in Nevada compared to California 
(p=0.031) (Table 2). However, among pap testing there was an almost 7% increase in pap testing 




        Figure 4. BRFSS screening proportion rates (%) through time for California, Nevada, and the US.  
 
 
Vaccine Usage by Sociodemographic Subgroups 
 Results also indicate that in Nevada, California and the U.S., American Indian/American 
Native, Asians and Blacks were the three lowest reported race subgroups with vaccine usage 
(Table 3). There were 2478 American Indian/American Natives reported in the U.S.; however, 
estimates were not reported in Nevada in California for some race groups because data was 
either not collected or because the denominator for the unweighted sample size was 0.588 (Table 
3). The highest reported race to get an HPV vaccine was White non-Hispanics followed by 
Hispanics in the U.S. (67.1% and 17.6%, respectively), and in Nevada (48.9% and 51.1%, 
respectively) (Table 3). Nevada and the US had over 60% vaccine coverage overtime in White 
teens compared to below 60% coverage in California (Table 3). The vaccine estimates for 
Hispanic teens living in California were much higher in recent years between 2016-2018 
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Table 3. Gardasil vaccine frequencies through time by sociodemographic subgroups. Numbers provided as n(%). 
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Note. AI/AN: American Indian/American Native. MSA: Metropolitan Statistical Area. 
Estimates for American Indian/American Native, Asians, or Black adolescents were not reported in Nevada or California for some race 
groups because data was either not collected or because the denominator for the unweighted sample size was 0.588 
 
 
When examining poverty status in the U.S., California and Nevada, the teens that were 
most vaccinated were those who lived at or above poverty (Table 3). A steady vaccine usage in 
California, Nevada and the U.S. in teens who lived at or above poverty status (Table 3). 2009 
had the highest number of teens living below poverty status who vaccinated in California (Table 
3). Unknown poverty status vaccine estimates were only reported in the U.S. The US had below 
1% vaccine estimates for all years in teens living in unknown poverty status (Table 3). California 
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and Nevada vaccine estimates were not reported for unknown poverty status because data was 
either not collected or because the denominator for the unweighted sample size was 0.588 (Table 
3). 
In the U.S., California, and Nevada, the majority of adolescents who received an HPV 
vaccine lived in a metropolitan statistical area (MSA) principal city (Table 3). Frequencies by 
subgroups can be seen in Table 3. Over time, California had over 50% vaccine coverage in teens 
living in an MSA non-principle city (Table3). The U.S. had approximately 40% vaccine 
estimates in teens who lived in a MSA non-principle city while Nevada had between 30 to 40% 
vaccine coverage over time (Table 3). Nevada had the largest number of teens living in an MSA 
principle city, followed by California and then the U.S. between 2008 through 2018 (Table 3). 
Given the reporting threshold, Nevada and California did not have vaccine estimates for teens 
living in a non MSA (Table 3). 
Associations between Vaccines Estimates and Screening Rates 
Trend analysis of screenings proportion rates with HPV vaccine coverage estimates do 
not show any association. No changes in cervical cancer screening rates have changed in 
Nevada, California or the U.S. since the introduction of the HPV vaccines in 2009 and 2014 
(Figures 5a-c). Therefore, we fail to reject the fourth null hypothesis that there will be no 
association between Gardasil vaccination rates and reported rates of cervical cancer screening in 




















Gardasil vaccine estimates compared to 
Cervical Cancer Screening Rates in California












Gardasil vaccine estimates compared to 
Cervical Cancer Screening Rates in 
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Gardasil vaccine estimates compared to 
Cervical Cancer Screening Rates in the U.S.




 Frequencies of adverse events (A.E.) in California, Nevada, and the U.S. by year can be 
seen in Table 4. Table 7 shows the frequencies of males, females, and those with no reported 
gender; however, in this study, only those who had gender specified were analyzed. When 
comparing the top 10 adverse events in the U.S. and California had 9 out of 10 of the same 
adverse events compared to 8 out of 10 for Nevada (Table 4). The ninth most common adverse 
event reported in the last 10 years in California was pallor (1.51%), which was not one of the top 
10 reported AE in the U.S. Nevada reported falls (2%) and abdominal pain (1.73%) as part of 
their top 10 most common AE, which were not part of the U.S. top ten AEs (Table 4).   
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 This study also found a decline in reported adverse events between 2008-2011 in the US 
(Table 4). We also found that there was no change overtime in reported adverse events between 
2011-2014 in the US (Table 5). However, in 2014 we saw that there was a steady increase in 




- - - - - 19 
(23.2) 
6 (7.69) 17 
(20.5) 




- 1 (0.806) - - - 17 
(20.7) 
5 (6.41) 17 
(20.5) 





2 (1.61) 3 
(6.67) 
- 6 (14.3) 2 (2.44) 8 (10.3) 6 (7.23) 4 (5.00) 8 (22.9) - 
Dizziness 4 
(5.33) 
2 (1.61) 2 
(4.44) 
2 (4.26) 2 (4.76) 2 (2.44) 1 (1.28) 3 (3.61) 4 (5.00) 3 (8.57) 4 (6.78) 
Syncope 3 
(4.00) 
1 (0.806) 4 
(8.89) 
1 (2.13) 2 (4.76) 3 (3.66) 1 (1.28) 2 (2.41) 5 (6.25) - 6 (10.2) 
Headache 2 
(2.67) 
5 (4.03) 2 
(4.44) 
1 (2.13) 2 (4.76) 2 (2.56) 2 (2.56) 1 (1.20) 3 (3.75) 1 (2.86) 1 (1.69) 
Fall 1 
(1.33) 
2 (1.61) 3 
(6.67) 
- 1 (2.38) - 1 (1.28) 2 (2.41) - 1 (2.86) 4 (6.78) 
Nausea 2 
(2.67) 
3 (2.42) 1 
(2.22) 
1 (2.13) - 3 (3.66) 1 (1.28) 1 (1.20) 1 (1.25) 1 (2.86) 1 (1.69) 
Abdominal 
Pain 
- 3 (2.42) 2 
(4.44) 
2 (4.26) - 1 (1.22) 2 (2.56) - - 1 (2.86) 2 (3.39) 
Erythema 2 
(2.67) 























































































































17 (2.22) 7 
(1.65) 
6 (1.99) 16 
(1.97) 




6 (1.39) 6 (1.27) 3 (1.17) 
Pyrexia 17 
(1.77) 
7 (0.915) 4 
(0.94
6) 
6 (1.99) 18 
(2.22) 












8 (1.05) 9 
(2.13) 
6 (1.99) 11 
(1.36) 
2 (2.56) 10 
(1.28) 
9 (1.48) 8 (1.85) 7 (1.48) 4 (1.55) 
Erythema 15 
(1.56) 






1 (1.28) 15 
(1.92) 
8 (1.32) 5 (1.16) 8 (1.69) 2 
(0.778) 
Note. Percentages may not be equal to 100% due to rounding.  
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(Table 6). Nevada reported the lowest number of adverse events between 2010-2012 compared 
to a drop in AE in 2013 in California (Table 5). Nevada, California, and the U.S. all showed a 
decline in reported adverse events in 2017 (Table 5). However, Nevada reported an increase in 
adverse events in 2018 (7.87%) compared to 2017 (4.67%) (Table 5).  
 
 



























































































Note. Row percentages may not add up to 100% due to rounding.  
 
 
Among sex, female adverse event reporting (AER) is approximately 30% higher than that 
of male AER between 2015 through 2018 (Table 6). In Nevada, female vaccine estimates are 
below California and US estimates, but male vaccine estimates are above California, and the 
U.S. vaccine estimates (Table 6).  
 
 










































































9 (2.13) 5 (1.66) 24 
(2.96) 



































































































































Total 22026 14420 11102 9067 9335 10328 11559 13690 15727 11877 10096 
Note. Unk: Unknown gender. 
 
 
Associations between Adverse Events and Gardasil Vaccine Estimates 
 Adverse event reporting increases correlate with vaccine coverage estimates by gender. 
There was a higher reported adverse event in males following introduction of a new vaccine after 
2009 and after 2014 (Table 6). The U.S. and Nevada had an almost 20% increase in vaccine 
coverage between 2014 and 2018 compared to an approximately 13% increase in California 
(Table 6). In Nevada, we found a slight correlation between the increase in vaccine estimates 
was following by an increase in adverse events only between 2008-2009 (Figure 6a). Our study 
found that an increase or decrease in vaccine estimates was followed by an increase or decrease, 
respectively the following year in California (Figure 6b). In the U.S., there were no correlations 
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Association Between  Gardasil Vaccine 
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Overall, there has been a 30.2% increase in vaccine coverage for females in Nevada, 
California and the U.S. combined since 2008. In 2017 California had almost 10% decrease in 
vaccine coverage, where Nevada had an approximately 5% decrease. However, males have seen 
over 50% increase in vaccine coverage since the Advisory Committee on Immunization Practices 
(ACIP) allowed boys to be vaccinated in 2009. The results of this study are consistent with other 
research findings. In 2011, there was high HPV vaccine coverage for at least one dose (53%) in 
females; however, there was a lower vaccine coverage (35%) for dose completion (3 doses) in 
the same year (Saraiya et al., 2013).  
This study only retrieved data for teens between the ages of 13-17 years; however, it is important 
to note the age distribution for vaccine uptake in the U.S. When considering the vaccine age 
distribution in the U.S. in 2018, a total of 18.5% of children 12 and younger, were vaccinated, 
25.6% of adolescents between 13-14 years were vaccinated, 34.5% of adolescents between 15-17 
years and 21.4% of adults 18-26 were vaccinated (Boersma & Black, 2020). With only 21.4% of 
adults getting the HPV vaccine and 78.6% of teens getting vaccinated, parental consent does not 
appear to be an obstacle for all underage persons (Boersma & Black, 2020).  However, only 
18.5% of those vaccinated in 2018 were 12 years or younger, indicating that there may be some 
barriers such as lack of parental knowledge, or misconceptions of the vaccine, which may cause 
parents to think their children will engage in risk sexual behavior (Boersma & Black, 2020). 
Cervical cancer screening proportions 
In this study, 76.1% of women in Nevada were screened for cervical cancer in the last 10 
years, while 81.3% and 79.6% were screened in California and the U.S., respectively. Overall, 
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there has not been a change through time with regard to cervical cancer screening after the 
implementation of the HPV vaccines. Saraiya and colleagues (2013) confirmed that screening 
levels may remain consistent since most providers use HPV testing with the Pap test annually. 
The large increase in cervical cancer screening in 2014 for Nevada was likely due to the change 
in the BRFSS questionnaire. In 2012, the BRFSS survey included women aged 18 and older and 
in 2014, questionnaire only including women aged 21-65 years who had a pap test in the past 
three years. There is a need to increase screening among younger women, various studies show 
that women aged 45 to 74 years and older are more likely to be screened than those who are 18-
44 years and 75 years and older (Miles-Richardson et al., 2017). Interventions that showed a 
notable increase in cervical cancer screening included those that were clinic-based, used lay 
health advisors (i.e., cancer survivors, members of churches, community members), and used 
behavioral theory (i.e., social influence theory, popular education and adult education theory) 
(Mann et al., 2015). 
         The reason for increase in pap screening is not entirely understood. However, the 
increase in screening in Nevada may be due to the change in the BRFSS question for cervical 
cancer screening in 2014. The question previously included women aged 18 years or older who 
got a pap test within the past 3 years and as of 2014, it only included women 21-65 years. No 
change in cervical cancer screening rates are likely due to the lag time between HPV vaccine age 
and the age (≥21 years) at which women begin having cervical cancer screenings. 
Gardasil vaccine coverage by sociodemographic subgroups 
This study continues to support research that there are health disparities among race, 
urbanicity and poverty status of teens who are vaccinated. American Indian/American Native 
(AI/AN) subgroup is the lowest subgroup in the U.S. to become vaccinated with HPV. In the 
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U.S., AI/AN make up only 1.4% of teens who have been vaccinated with an HPV vaccine in the 
last 10 years, followed by Asians (3.4%). White non-Hispanics continue to be the largest race 
subgroup who receives an HPV vaccine, followed by Hispanics (67.1% and 17.6%, 
respectively). Previous studies have assessed possibilities for the disparities in vaccine 
coverages. Issues with HPV vaccine coverage by race are affected by how parents perceive the 
vaccine. Research findings found that barriers for HPV vaccine administration was related to the 
concern that it would lead to premarital sexual activity (Galbraith et al., 2016). It is critical for 
health care providers to provide parents and adolescents with HPV vaccine education. Several 
studies reported that the recommendation from a health care provider to receive the HPV vaccine 
was a common reason for HPV vaccine administration among parents and adolescents 
(Alexander et al., 2014; Galbraith et al., 2016). 
         It is no surprise that those who are living at or above poverty have the highest vaccine 
coverage of adolescents. In California, Nevada, and the U.S., over 75% of teens vaccinated live 
at or above poverty, while approximately 20% of teens who have gotten an HPV vaccine live 
below poverty. Similar findings were reported that children with an employed parent, healthcare 
coverage and/or higher income were more likely to be vaccinated compared to children who did 
not have the above scenarios (Liddon et al., 2012; Shapiro et al., 2018). A study by Bhattacharya 
and colleagues (2019) found that a higher income level was highest among all women regardless 
of nativity status (being US- versus foreign-born). Higher estimates of vaccine in teens of higher 
SES are likely due to higher healthcare coverage, parent education, and overall ease of access to 
healthcare facilities. However, in a study done by Grandahl and colleagues (2017), they found 
that neither mother’s and father’s education status or occupation had a significant impact on 
males or female vaccine uptake in Sweden. The difference in vaccine update by SES status 
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between Sweden and the US may be due to Sweden’s national vaccine program where eleven 
vaccines (including the HPV vaccine) are given free of charge to children (Public Health Agency 
of Sweden, n.d.).  
  Overall, California is doing very well in terms of vaccine uptake for teens. This study 
indicates that in the last 3 years, California has been able to increase the vaccine rates for 
Hispanic adolescents above those of White adolescents. The large vaccine uptake in Hispanic 
adolescents may have related to decreased language barriers between physicians and patients 
given that the Hispanic population makes up 40% of their population (U.S. Census Bureau, n.d.). 
Additionally, California has implemented the use of the VFC program and the California Health 
& Wellness program, which allows adults (19 years or older) and their families to get vaccinated 
for free (California Health & Wellness, n.d.). Both of these programs cover the HPV vaccine for 
free at any pharmacy which broadens its availability for children, mid- to late-adolescents and 
adults. Nevada could start to make more tailored programs for each race/ethnic subgroup to 
attempt to bridge any language gaps so that each subgroup could make their own informed health 
decisions. 
 This study indicated that Nevada falls behind California’s vaccine and screening rates 
despite similarities in age and race/ethnic group proportions. One reason may be because Nevada 
has three urban and rural counties and 11 frontier counties, which demonstrates the highly 
underserved communities in the state. The sparsity of many of the hospitals and community 
health centers in Nevada’s rural and frontier countries causes longer travel times and distances to 
centers with specialized medical facilities. Hence, this may be the cause for less vaccine uptake 





         This study showed that the highest number of adverse events that have occurred in all the 
U.S., California and Nevada were non-serious events due to reasons such as incorrect vaccine 
given or a vaccine given to a male prior to accepted guidelines. Despite studies reporting high 
VTE adverse events, this study did not reveal VTE to be one of the top 10 AEs in the U.S., 
California, or Nevada (Lui et al., 2016; Mauro et al., 2019; Naleway et al., 2016). This study also 
did not find any AEs related to GBS in the top 10 reported AEs despite other research studies 
(Slade et al., 2009; Gee et al., 2017; Mauro et al., 2019). This study supports other research 
findings syncope, dizziness, headaches, nausea, vomiting, among the most common adverse 
events (Slade et al., 2009; Arana et al., 2018; Mauro et al., 2018; Suragh et al., 2018).  
Gardasil’s manufacturing company reports that the most common side effects included 
injection site pain, swelling, erythema, itching, bruising and reports of fever(pyrexia), abdominal 
pain, diarrhea, sore throat, tiredness and nausea (Merck & Co., Inc., 2020). The top three 
injection site reactions, for males and females receiving Gardasil (quadrivalent vaccine), were 
pain (61.4% and 83.9%, respectively), swelling (13.9% and 25.4%, respectively) and erythema 
(16.7% and 24.7%, respectively) (CDC, 2014a). This study maintains that the leading adverse 
events are non-serious. Arana and colleagues (2018) confirm that 94.2% of adverse event reports 
were non-serious supporting that the use of these vaccines is not in maleficence. 
Vaccine Perceptions 
There has been much controversy related to the HPV vaccine. Some of the 
misconceptions may be due to the age that was selected for girls to be vaccinated. The Advisory 
Committee on Immunization Practices (ACIP) recommended routine vaccines for girls as young 
as 9 years to allow for the vaccine to be administered prior to first sexual encounter (Saraiya et 
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al., 2013). There are parents with the perception of the vaccine creating the path of risky sexual 
behaviors for their children (Leidner et al., 2020). 
Canada has an HPV vaccine program that targets school-age children, resulting in high 
vaccine coverage (Saraiya et al., 2013). The ACIP has included HPV vaccines for the Vaccines 
for Children Program since October 2009, which covers the cost of the HPV vaccine for children 
younger than 18 years, who are uninsured, Medicaid-eligible, or who are American 
Indian/Alaska Native (CDC, 2020). Health insurances typically cover vaccines that are routinely 
recommended by ACIP, which can further assist increasing HPV vaccine coverages. 
         California Planned Parenthood Education Fund was established to help expand access, 
availability and affordability of the HPV vaccine (CPPEF, 2016). The AB 499 in California 
expands current legislation to include the HPV vaccine, and other STD prevention. AB 499 
allows teens 12 years and older to consent to receiving the vaccine in order to protect themselves 
against sexually transmitted diseases whereby the child’s parent or guardian is not liable to pay 
for medical care received by the minor (AB No. 499; CPPEF, 2016). There are also various 
organizations (i.e., California Medical Association, California Family Health Council, California 
Primary care Association, American Congress of Obstetricians and Gynecologists, District IX) 
making strides to try to increase HPV vaccine uptake (CPPEF, 2016). 
         Nevada has not implemented any statewide legislation for the requirement of the HPV 
vaccine in adolescents. There has been recent pushback in the Nevada Legislature Legislative 
Committee on Health Care. During the third meeting of the Legislative Committee on Health 
Care for the 2019-2020 Interim, several public comments reporting severe adverse events 
opposing the use of the HPV vaccine (LCHC, 2020). 
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         Overall, the U.S. is making strides in making the HPV vaccines accessible to adolescents. 
Washington D.C., Puerto and 48 U.S. states allow pharmacists to administer the HPV vaccine in 
children (NCSL, 2020). However, there continues to be only 3 states (RI, HI, VA), Washington 
D.C. and Puerto Rica that require the HPV vaccine for school attendance. There is a need for 
better education that targets specific subgroups and cultural differences. (NCSL, 2020). 
Limitations 
         As is to be expected, there are limitations found in this study. All TeenVaxView data are 
self-reported increasing the likelihood of recall bias because parents may not remember all of 
their child’s vaccine record history. It is also likely that this study contains selection bias since 
some parents may not report vaccine history due to a lack of trust, knowledge, or cultural beliefs 
about HPV. Additionally, differences in sociodemographic data, lifestyle, and medical practices 
may exist in parents who choose to vaccinate their child with Gardasil versus parents who opt-
out. 
Furthermore, given that there was a follow-up questionnaire sent to physicians in the 
NIS-Teen, there is the potential for losses to follow-up. Losses to follow-up could be due to 
differences in referral criteria, improper procedures for cases, or sociodemographic information, 
which could lead to misclassification bias. Another limitation of this study is the possibility of 
underreporting or sample bias in those who file an adverse event report compared to those that 
do not. There is also the limitation that may be caused by unevaluated dosing effects from HPV 
vaccine administration given missing or unreported data. 
We also expect to see limitations due to self-reporting data obtained from BRFSS. 
Respondents may not report accurate information. Question wording may lead to measurement 
error or time lapse between survey and a particular event may lead to response error in BRFSS. 
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However, given the complexity of sampling through random-digit dialing, the BRSS offers 
several advantages such as obtaining generalizable population. 
Additionally, the use of VAERS data presents limitations due to VAERS’ passive 
reporting system. Since VAERS relies on individuals to report any adverse events associated 
with a vaccine, it’s use is not to determine if a vaccine caused a health problem, but rather for 
detecting any unusual patterns of adverse events. Hence, limitations associated with VAERS 
includes reporting bias and sampling bias. Severity of an adverse event is subjective and can 
result in measurement error. Additionally, sampling bias could result since those who report to 
VAERS may not be the same as those who do not report adverse events thus leading to less 
generalizability. Our study was not able to assess incidence of adverse events given that VAERS 
lacks information on the total number of people who are vaccinated and those people who 
experience an AE. 
Lastly, given that correlation will be used to test for potential temporal associations for 
hypotheses three and four, this data should be interpreted cautiously given this data is strictly 
correlational and will be used for the basis of future hypothesis-generating results. Although this 
study assessed Gardasil vaccine rates and screening rates together, we expect there to be a lag 
time between when we can see more accurate screening rates given that the lag time between 
vaccine age and screening age do not align. 
Future Public Health Policy and Research Recommendations 
         The present study illustrates the ongoing disparities among adolescents based on SES, 
race/ethnicities, and urbanicity that has been seen in previous years in the U.S. As of 2020 
policies requiring HPV vaccination in school-aged children has not reached by all U.S. states. 
With only three states and Washington D.C. requiring HPV vaccination to enter secondary 
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school, there is a need to consider statewide school mandates that will increase vaccine uptake in 
school-aged children prior to their first HPV exposure (Immunization Action Coalition, 2019). 
There has been increase in the analysis of effective policy efforts to try to increase vaccinate 
coverage across the U.S. Saulsberry and colleagues (2019), found that parents preferred a 
physician mandate, which would require physicians to offer the HPV vaccine (p<0.01) compared 
to middle school mandates, which would require students to get vaccinated in school. Policy 
makers should ensure that federally funding vaccine programs be provided to all school-aged 
children nationwide. Existing currently is the Vaccines for Children Program (VFC), which 
provides the vaccine at no cost to American Indian/Alaskan Native, uninsured, Medicaid-
eligible, or underinsured children (less than 18 years). Despite the VFC program, states vary in 
their supply of the vaccine and determination of vaccine eligibility. However, Dorell and 
colleagues (2013) determined that when comparing VFC program funding, states that provided 
universal vaccine coverage had higher HPV initiation rates. Some states are only able to supply 
eligible children through VFC criteria only (noted above). There are other states who use state 
and local funds to supply the VFC program making uninsured children and those who meet VFC 
criteria eligible, and other states have universal (VFC-eligible, underinsured, and privately 
insured children) coverage through the use of state and local funds to supplement the VFC 
program (Dorell et al., 2013). Mandated education in schools has not shown any significant 
increase in vaccine coverage for girls before or after the mandate (Pierre-Victor et al., 2017). 
While it is important to education parents and children on the benefits of the HPV vaccine, 
mandated education should be supplemented with physician mandates to discuss HPV vaccine 
benefits. Discussions about HPV vaccine eligibility, social stigma and parent preferences are 
three factors that influence this decision-making process. 
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Mortality in cervical cancer has gone down in the last couple of years (Sawaya & 
Huchko, 2017). The decrease in morality may be due to better treatment of cervical cancer, early 
screening before the cancer is in the late stage. It is also possible that we will see more decrease 
in morality of cervical cancer through vaccine uptake. Despite the importance that all those 
factors play in the decrease of cervical cancer mortality, we did not look at morbidity/mortality 
in this study because that data was not available for us to use. However, future studies need to be 
done to assess the change in mortality of cervical cancer in Nevada once all vaccinated girls have 
reached screening ages (i.e., in the year 2021 and further or an approximate time lag of 10 years 
between 9-21years).  
         To the author’s knowledge, there have no previously published studies that analyze state-
specific data on Gardasil vaccine coverage, adverse events and screening that compares Nevada, 





 The data used in this study supplemented current research with the most recent data 
available for Nevada, California, and U.S. This study found that screening rates have not 
decreased; however, future studies should assess screening rates in 2021 and further to capture 
all girls vaccinated with the HPV vaccine. Of the three locations analyzed, California showed to 
have the highest vaccine estimates through time compared to Nevada and the U.S., which is 
likely due to variations in state demographics. It would be interesting to assess each state by 
demographics along with the current vaccine programs in place. No association was seen 
between Gardasil vaccine estimates and cervical cancer screening rates in this study. This study 
showed a temporal association between adverse events and Gardasil vaccine estimates in 
California only. Furthermore, this project provides information on adverse events that could 
further support legislation to create a vaccine program nationally that better targets subgroups. 
This project also shows the need to target American Indian/American Native subgroups given 
their extremely low vaccine rates despite current child vaccine programs. Finally, given the 
largely descriptive nature of this study, the main outcomes provided hypothesis generating 
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